Price$252.68+0.31 (+0.12%)
01:30 PM07:45 PM
News · 26 weeks141+127%
2026-01-112026-07-05
Mix7090d
- Other44(63%)
- Insider13(19%)
- SEC Filings7(10%)
- Earnings3(4%)
- Analyst2(3%)
- Dividends1(1%)
Latest news
25 items- SECAbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaTEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting, offering a chemotherapy-free optionIn the Phase 3 EPCORE® FL-1 trial, fixed-duration TEPKINLY + R2 achieved statistically significant improvement of progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete responseNORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combin
- INSIDERSEC Form 4 filed by Director Rapp Edward J4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERSEC Form 4 filed by Director Quaggin Susan E4 - AbbVie Inc. (0001551152) (Issuer)
- PRA Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics OpportunityIssued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ:CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of its CXU™ regenerative tissue platform, a single technology the company is designing to scale across soft-tissue restoration markets spanning aesthetics and body contouring, wound care, and breast reconstruction. RENO, Nev., July 01, 2026 (GLOBE NEWSWIRE) -- Biotech Insider, Medical aesthetics has become one of the most closely watched corners of healthcare, drawing established pharmaceutical and device makers into soft-tissue restoration, contouring, and reconstruction. Against that backdrop,
- PRAbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaTopline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCLNORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab plus gemcitabi
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-16) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/26/2026. Application Category: BLA, Application Number: 761262, Application Classification:
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-45) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/26/2026. Application Category: BLA, Application Number: 761105, Application Classification:
- PRAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia AreataPositive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 241,2Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 241,2NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once
- PRAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental VitiligoIf approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune diseasePositive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in which upadacitinib achieved both co-primary endpoints demonstrating at least a 50% improvement in total body repigmentation (T-VASI 50) and at least a 75% improvement in facial repigmentation (F-VASI 75) from baseline at week 481NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Hu
- PRSKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic DiseaseSKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kgSKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older w
- PRAbbVie to Host Second-Quarter 2026 Earnings Conference CallNORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas incl
- PRThe Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for ItIssued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc. (NASDAQ:CNXU) is positioning its regenerative CXU™ platform to compete for it. NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Biotech Insider — In emerging medical markets, the most telling signal is not the small company making the bold claim — it is the giant quietly proving the claim is real. That is exactly what has happened in aesthetics. Galderma, the pure-play dermatology leader behind Sculptra and Restylane, has been presenting interim clinical data demonstrating that i
- SECSEC Form 11-K filed by AbbVie Inc.11-K - AbbVie Inc. (0001551152) (Filer)
- PRBOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking ProgramBOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next LevelIRVINE, Calif., June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in women businessowners. This year's cohort was selected from a highly competitive and t
- PRAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsCanada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar linesBoey® offers a differentiated treatment option for many people who are curious about facial injectablesResults may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBOTOX Cosmetic® (onabotulinumtoxinA) is the only neurotoxin clinically tested for use following treatment with Boey®IRVINE, Calif., June 23, 2026 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE:AB
- PRAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus InfectionMAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older.The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer.As the only treatment approved in the EU for both acute and chronic HCV infection, MAVIRET may help streamline care pathways and support broader efforts to advance HCV elimination goals.NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE
- PRAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque PsoriasisSKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas2,3NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older w
- SECAbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioProposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie
- PRAbbVie Declares Quarterly DividendNORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable August 14, 2026, to stockholders of record at the close of business on July 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges
- PRFresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma FirepowerIssued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
- PRAllergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck AppearanceSKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1"This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1IRVINE, Calif., June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the a
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-44) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761105, Application Classification:
- FDAFDA Approval for SKYRIZI issued to ABBVIE INCSubmission status for ABBVIE INC's drug SKYRIZI (SUPPL-15) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761262, Application Classification:
ABBV FAQ
8 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.Does ABBV pay a dividend?
Yes. ABBV's next ex-dividend date is 2026-07-15 with a declared cash dividend of $1.73 per share, payable 2026-08-14.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-04-30.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.